Defaz

Quick links to important sections

Defaz

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Defaz

Quick Facts

Property Description
Active Ingredients Folic Acid, Zinc Sulfate, Carbonyl Iron
Form Oral Capsule (often timed-release)
Pharmacological Class Hematinic, Mineral and Vitamin Combined Preparation
Common Use Prophylaxis and management of nutritional deficiencies
Origin Synthetic (Folic Acid) and Mineral Derivatives

What Type of Preparation is Defaz?

Defaz is formally classified as a specific mineral and vitamin combined preparation and a hematinic, which establishes its role as an oral nutritional supplement. It is a combination product that supplies three essential micronutrients—Folic Acid, Zinc, and Iron—in a single capsule. The product is manufactured as an oral capsule and is often provided in a timed-release formulation, a specific design choice recognized in pharmacology for improving patient tolerance and absorption kinetics. This approach focuses on optimizing the delivery of the combined components for systemic health.

The Core Components of Defaz: Iron, Folic Acid, and Zinc Sulfate

The three main active ingredients are Carbonyl Iron, Folic Acid, and Zinc Sulfate. Folic Acid is the synthetic form of Vitamin B9, which is vital for cell production. The formulation distinguishes itself by utilizing Carbonyl Iron, an elemental form that is clinically recognized for its high purity and reduced toxicity risk compared to traditional iron salts, as its absorption is more regulated. This inclusion of Elemental Iron in a bioavailable form is a defining characteristic of Defaz when compared to older, less tolerated iron supplement formulations.

General Purpose: Why is this Combination Used?

The general therapeutic purpose of Defaz is the prophylaxis and correction of documented, concurrent nutritional deficiencies of iron, folate, and zinc. This combined strategy is widely supported in medical practice for addressing depletion where multiple micronutrient deficits are suspected. Iron and Folic Acid are crucial for the efficient formation of red blood cells (erythropoiesis), while Zinc contributes significantly to immune function and metabolic activity. Defaz is typically used when a patient requires a comprehensive approach to restoring these interdependent nutritional cofactors.

Regulatory References

  1. NIH DailyMed: Carbonyl Iron

What side effects are possible with Defaz?

Possible Side Effects and Safety Information

The safety profile of this iron, folic acid, and zinc combination preparation, as documented in regulatory sources, is primarily defined by gastrointestinal disturbances. These effects are officially classified as Common.

Adverse Reaction Categories

Classification System-Organ Class Examples Documented in Labeling
Common Gastrointestinal Disorders Nausea, constipation, diarrhea, abdominal discomfort, and vomiting.
Rare Immune System Disorders Hypersensitivity reactions, including rash, pruritus, and anaphylaxis.

It is an expected safety observation that the presence of elemental iron causes the darkening of stool (black stools), which is not classified as an adverse reaction.

Serious Reactions and Safety Constraints

Serious adverse reactions, such as anaphylaxis and anaphylactic shock, are documented as rare events. The most critical safety concern noted in official labeling relates to the risk of acute iron overdosage, which is cited as a leading cause of accidental poisoning in children under six years old.

Specific safety considerations must be observed based on population and condition. Folic acid alone may mask an underlying untreated Vitamin B12 deficiency, delaying diagnosis and potentially leading to neurological consequences. The medicine is contraindicated in patients with known iron overload conditions like Haemochromatosis. For elderly patients, the risk of constipation potentially leading to faecal impaction is a safety note associated with continual administration. Gastrointestinal effects are often noted as being temporary, typically improving as treatment continues.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations: Acute overdose may present with severe gastrointestinal distress, including nausea, vomiting (potentially with hematemesis), abdominal pain, and diarrhea. Systemic effects can rapidly progress, involving tachycardia, hypotension, lethargy, and evidence of metabolic acidosis.

Physiological systems affected (as stated in label): Officially documented systems affected include the Gastrointestinal tract, Cardiovascular system, Central Nervous System, Hepatic system, and Renal system.

Dose-related or exposure-related factors (if applicable): Overdose risk is associated with the ingestion of large amounts of iron.

Population-specific overdose notes (if applicable): Iron-containing products are a leading cause of fatal poisoning in children younger than age 6.

Emergency-response statements (as written in official documents): Management involves symptomatic and supportive treatment. Deferoxamine is documented as the specific chelating agent for treating severe Iron toxicity. Procedures such as whole-bowel irrigation (WBI) may be considered.

When immediate medical help is required (label-derived phrasing only): Suspected overdose requires immediate medical attention. Contact emergency services immediately if the patient collapses, has trouble breathing, or is unresponsive. Hospitalization is required for significant symptoms or confirmed toxic ingestion.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The potential for severe and life-threatening toxicity, including circulatory collapse and death, is explicitly documented.

Regulatory basis (EMA / FDA / etc.): Based on the safety data and Prescribing Information as mandated by regulatory authorities.

Overdose-context constraints (as defined in official documents): Requires continuous hospital monitoring, including serial checks of serum iron concentrations and organ function.


Resulting Overdose Structure

Official overdose statements:

  • Suspected overdose requires immediate medical attention and hospitalization due to the potential for severe gastrointestinal toxicity and systemic failure.
  • Life-threatening outcomes include shock, metabolic acidosis, hepatic necrosis, and coagulopathy.
  • Deferoxamine is documented as the specific chelating agent for treating severe Iron toxicity, and the overall management approach is defined as symptomatic and supportive.
  • The product carries a specific regulatory warning about the potential for fatal poisoning in children younger than age 6.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile through the rapid progression from initial corrosive injury to potential systemic failure, including circulatory collapse and organ damage. This high-risk classification necessitates the regulatory mandate to seek immediate medical attention and defines the required hospital interventions, such as organ function monitoring and the use of the documented Iron antidote.

Therapeutic Uses of Defaz

What Defaz Treats: Main Uses and Benefits

Defaz is a combined preparation used for targeted nutritional intervention, providing support to manage specific states of deficiency and their resulting symptoms. Its therapeutic benefit is commonly used to help with support for systemic balance during periods of high physiological demand. Iron deficiency anaemia is generally characterized by symptoms of tiredness and lack of energy, highlighting the primary symptomatic domain the preparation is designed to address.

Therapeutic Focus and Scenarios

The preparation is commonly used to help with iron-deficiency and folate-deficiency anemias, including the accompanying systemic symptoms like chronic tiredness, generalized physical weakness, and low stamina. This support extends to clinical scenarios requiring significant nutritional replenishment, such as use during pregnancy and lactation, post-surgical recovery, or after blood loss.

Addressing these multiple, interdependent deficits may help support immune system function and functional stability. This preparation is commonly used to provide supportive nutritional assistance that helps ease the overall symptom burden associated with chronic deficiency. The preparation is applied in addressing symptoms related to systemic imbalance and may assist with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Deficiency Symptoms
Symptom Focus Chronic tiredness, low energy, physical weakness, poor concentration related to deficiency.
Clinical Use Correction of documented Iron, Folate, and Zinc deficiencies; prophylaxis in high-demand states.
Patient Benefit Supports maintenance of functional stability; assists with easing the symptom burden of low energy.

Regulatory References

  1. NHS guidance on iron deficiency anaemia

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Deflazacort

This section outlines population eligibility and non-eligibility strictly based on authoritative government regulatory documents.


Absolute Contraindications

Deflazacort is contraindicated (must not be used) in patients with a known hypersensitivity to the drug or any of its inactive ingredients. Use is also strictly contraindicated for patients receiving immunosuppressive doses who are also scheduled to receive live or live attenuated vaccines.

Age and Condition Restrictions

Population Group Eligibility Status (Regulatory Basis)
Pediatric Patients Safety and effectiveness are not established for patients under 2 years of age.
Hepatic Impairment No dose adjustment is required for mild or moderate impairment; use in severe impairment has not been studied (Not Established).
Renal Impairment No dose adjustment is required for mild, moderate, or severe impairment.

Conditional Use

Use of Deflazacort requires caution and professional risk assessment in patients with or at risk for: active infections (including latent tuberculosis, ocular herpes simplex), certain gastrointestinal disorders (e.g., active peptic ulcers), heart failure, and hypertension. For pregnancy and lactation, use is conditional and only recommended if the clinical benefit to the mother outweighs the potential risks to the fetus or infant, as human data is limited.

What should I know about interactions with other medicines?

The official regulatory profile for Defaz, a combined preparation of Iron, Folic Acid, and Zinc, is structured by pharmacokinetic interactions, primarily chelation and reduced absorption of co-administered medicines.

Official Interaction Statements

Classification Interacting Entity Interaction Outcome
Contraindicated Combination Undiagnosed Anemia Folic Acid may mask the hematological signs of deficiency, potentially allowing severe neurological complications to progress.
Pharmacokinetic (PK) Tetracyclines, Quinolones The mineral components chelate with these antibiotics, significantly reducing the absorption of both Defaz components and the antibiotics.
Pharmacokinetic (PK) Antiepileptics (e.g., Phenytoin) Folic Acid co-administration is documented to reduce the plasma concentrations of these medicines.

Interaction Constraints and Considerations

The absorption of Iron and Zinc is officially noted to be reduced by various substances, necessitating timing separation rules. Co-administration with Antacids, H-Blockers, or Proton Pump Inhibitors (PPIs) may decrease the absorption of both Iron and Folic Acid. The absorption of Iron and Zinc is also impaired by specific food components such as coffee, tea, milk, and whole-grain breads.

Timing-based interaction rules are mandated for certain co-administered agents. The product components must be separated from Tetracyclines, Quinolones, Cephalexin, and Ceftibuten by at least 3 hours. A caution exists regarding the potential risk of zinc accumulation in patients with renal dysfunction.

Mechanism of Action

How Defaz Works

Molecular Mechanism in Erythropoiesis

This domain centers on providing Elemental Iron for the Heme component of Hemoglobin and Folic Acid as a crucial cofactor for the DNA synthesis required for cellular division. By supplying these interdependent, rate-limiting components, the mechanism influences the final maturation of erythrocytes and establishes the systemic capacity for functional oxygen transport potential.


Action on Cellular Proliferation and Genomic Processes

The mechanism involves Folic Acid influencing one-carbon metabolism to synthesize DNA precursors, complemented by Zinc integration into hundreds of metalloenzymes, including those necessary for replication ( DNA/RNA polymerases). This combined activity influences the accuracy of cell division, particularly in rapidly regenerating tissues, and contributes to the structural and functional state of high-turnover cells.


Integration into Immune and Metabolic Enzyme Function

The preparation's components act synergistically by replenishing catalytic ions and cofactors, enabling the function of diverse enzymes like Superoxide Dismutase (SOD) for antioxidant defense and Cytochrome oxidase for mitochondrial energy output. This pervasive mechanism influences cellular homeostasis and supports metabolic pathways by enabling widespread enzymatic activity.

Dosage and Administration Information

How to Use Defaz

Defaz is administered via the oral route as a fixed-combination capsule containing 50 mg Carbonyl Iron, 0.50 mg Folic Acid, and 22.5 mg elemental Zinc. The standard daily regimen is one capsule, once daily, establishing the frequency pattern for nutritional replenishment.


Administration Scope

Feature Official Guideline
Dosing Regimen One capsule daily (fixed-dose combination).
Timing in Relation to Meals Typically administered before food for optimal absorption, though consumption with food may be necessary to improve gastrointestinal tolerance.
Special Procedural Conditions The capsule must be swallowed whole and not crushed or chewed to preserve the integrity of the timed-release coating. Co-administration should be separated from substances like antacids or dairy products, which can interfere with iron absorption kinetics.
Population-Specific Use The standard daily dose is applied for deficiency management and prophylaxis during high physiological demand states, notably pregnancy and lactation. Administration in the first trimester requires documentation of definite iron deficiency.
Missed Dose Rule If a daily dose is missed, it is generally advised to continue with the next scheduled dose at the regular time.

Resulting Procedural Structure

The official instructions establish a standardized protocol for administration, mandating a fixed once-daily oral capsule regimen. This approach ensures the correct dose of the three active components is delivered consistently and defines the essential procedural steps, such as swallowing the capsule whole and timing it relative to meals. The treatment course duration is defined by the required period of nutritional correction or ongoing prophylaxis.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Defaz


Research Evidence for Iron and Folate Deficiency Anemias

Research has studied this combination preparation, or its core components, in populations with low levels of iron and folate in the blood, including those with deficiency-related symptoms like chronic tiredness or physical weakness. These studies monitored changes in key blood markers that reflect nutritional status, such as Hemoglobin and Serum Ferritin.

The available evidence comes primarily from short-term Randomized Controlled Trials (RCTs) and systematic reviews that explored how supplementation with these micronutrients was associated with movements in these blood values in deficient adults. Findings describe patterns observed in the studies where supplementation was associated with movements in these hematologic markers. The specific elemental form of iron used in Defaz, Carbonyl Iron, was evaluated in some research for its absorption profile and characteristics against other iron forms. Research so far suggests that these studies focus heavily on laboratory changes and are often short-term, meaning long-term effects are not fully established.


Research Evidence for Nutritional Prophylaxis During Pregnancy

The use of combined supplements during pregnancy was studied for nutritional prophylaxis and for exploring its association with maternal and infant outcomes. This research often takes the form of large-scale Randomized Controlled Trials and comprehensive meta-analyses.

Studies research examined how supplementation was associated with the mother's iron and folate nutritional markers late in pregnancy. Research findings indicate that supplementation with Iron and Folic Acid was associated with supporting the mother's nutritional markers during this period of high demand. However, the findings regarding the incremental effect of adding Zinc to the Iron and Folic Acid combination were mixed across various trials and populations, meaning the certainty regarding the added value of the Zinc component for certain outcomes remains low in broad populations.


Study Populations and Research Gaps

Available research primarily focuses on short-term symptom changes. Limited information is available on how durable any nutritional patterns might be once supplementation is stopped. A key research gap is that the comparative evidence is lacking for large-scale, dedicated trials that test this specific combination against other standard single-nutrient or two-nutrient treatments. Furthermore, the results apply only to the populations studied, meaning the findings are difficult to generalize.

Key Studies & References

  1. Daily oral iron and folic acid supplementation is recommended for pregnant women to prevent maternal anaemia, puerperal sepsis, low birth weight, and preterm birth (WHO Guideline)

Frequently Asked Questions (FAQ)

Common questions about Defaz (FAQ)


Q: Is Defaz a steroid, and if so, what kind?

According to official regulatory classifications, Defaz is categorized as a mineral and vitamin combined preparation and a hematinic. It contains Carbonyl Iron, Folic Acid (Vitamin B9), and Zinc Sulfate. Defaz is not a steroid medication.


Q: Does Defaz affect sleep patterns, like causing insomnia or vivid dreams?

The official product documentation outlines the common and rare adverse effects of Defaz. These lists do not currently include insomnia, vivid dreams, or other sleep-related disturbances as a reported adverse reaction.


Q: What kind of scientific research supports the use of Defaz for its main condition?

The evidence for Defaz's use is drawn from scientific reviews and short-term Randomized Controlled Trials (RCTs). These studies primarily focus on monitoring changes in key blood markers, such as Hemoglobin and Serum Ferritin, in adults and pregnant individuals who have known deficiencies.


Q: Is it safe for older adults (seniors) to take Defaz?

Official labeling includes specific safety considerations for older adults. Regulatory cautionary statements note a concern regarding the risk of constipation potentially leading to faecal impaction for elderly patients when the supplement is taken continually.


Q: Why do doctors prescribe Defaz instead of older, more well-known drugs sometimes?

Official descriptions note the use of Carbonyl Iron, an elemental iron form that is clinically recognized for its high purity and potentially reduced toxicity risk when compared to traditional iron salts.


Q: Is it normal to have a metallic taste in the mouth after taking Defaz?

While a metallic taste is a sensation sometimes associated with zinc supplementation, it is not explicitly listed as either a common or rare adverse reaction in the official safety documentation for the Defaz combination product.


Q: Is the effectiveness of Defaz affected by food—should it be taken with or without a meal?

Official administration guidelines indicate that it is typically taken before food for optimal absorption. However, consuming it with food may be recommended for some users to improve gastrointestinal tolerance.


Q: Are there any known drug-drug interactions with common antidepressants?

Although the documentation does not specifically list antidepressants, the interaction profile does show that the Folic Acid component is known to reduce the plasma concentrations of certain other Central Nervous System (CNS) drugs, such as antiepileptics. This establishes a known precedent for Folic Acid-related interactions with CNS medications.


Q: Does Defaz affect the immune system in a noticeable way?

The product's components are known to play a role in biological processes. The zinc component is integrated into various metalloenzymes that help support immune function and metabolic activity.


Q: Is there a risk of developing bone density issues while on Defaz?

The official safety profile for this combined nutritional supplement does not list bone density issues or any musculoskeletal problems as a common or rare adverse reaction.


Q: Can Defaz cause or contribute to heartburn or stomach upset?

As a mineral supplement, Defaz is associated with potential gastrointestinal effects. The official safety profile explicitly lists several common disturbances, including nausea, constipation, diarrhea, abdominal discomfort, and vomiting.


Q: Is it common to feel more energized or, conversely, fatigued when taking Defaz?

The therapeutic purpose of Defaz is to supply components that influence the body's capacity for oxygen transport. This action is intended to address deficiency-related symptoms, which can include conditions like chronic tiredness or physical weakness.


Q: Does Defaz interact with alcohol, and what are the risks?

Official information on interactions primarily notes the Folic Acid component. Regulatory documentation indicates that moderate consumption of alcohol may increase the rate of folic acid elimination and decrease its absorption.


Q: Does Defaz change how other medications are absorbed in the body?

Regulatory statements confirm that the mineral components of Defaz can chelate (bind) with certain medications, such as specific antibiotics (Tetracyclines, Quinolones). This interaction can reduce the absorption of both the antibiotic and the components of Defaz.


Q: Are Defaz users more prone to infections?

The zinc component is known to support immune function. Furthermore, increased susceptibility to infection is not listed in the product's official common or rare adverse reactions.


Q: Is Defaz available in different forms, like liquid or chewable tablets?

The official product labeling specifies that Defaz is administered as an oral capsule. It is often provided in a timed-release formulation to optimize absorption and patient tolerance.

How should Defaz be stored and disposed of?

The official labeling for Defaz (Carbonyl Iron, Folic Acid, Zinc Sulfate capsules) specifies mandatory storage and disposal rules to maintain product quality and safety. The medicine must be kept in a cool and dry place, protected from light and moisture. The required storage temperature is below 30 C. Due to its iron content, it is strictly required to store Defaz out of the sight and reach of children to prevent accidental poisoning.


For disposal, do not flush unused or expired Defaz down the toilet or pour it into a drain. The official procedure is to use a community drug take-back program. If one is unavailable, the product should be mixed with an unappealing substance, placed in a sealed container, and then discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Defaz found in:

A-Z Index: